Skip to main content

CD19.CAR T Cells

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

  • RegistryNCT03676504
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionAcute Lymphoblastic Leukemia, Adult
  • SponsorUniversity Hospital Heidelberg
How CD19.CAR T Cells worksNCT036765042 min

What the film says

Read the transcript

CAR T cells against CD19 are now standard for some relapsed leukemias and lymphomas. Most carry one of two co-stimulatory signals, and are made by companies at high doses.

The idea: give the cells both signals at once, make them in the hospital's own lab, and ask how few are enough.

At Heidelberg University Hospital, patients' T cells receive a third-generation receptor carrying CD28 and 4-1BB together, aiming for longer-lived cells. Doses were escalated across adults and children.

In thirteen adults with relapsed acute lymphoblastic leukemia, eight of ten evaluable reached complete remission with no neurotoxicity. In nine heavily pretreated CLL patients, six reached complete remission.

HD-CAR-1, led by Michael Schmitt, continues in Heidelberg, from age three. Public record; not medical advice.

Sources behind this film

Show 2 more sources

The drug

What is being tested.

Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2

3 days of cyclophosphamide 500 mg/m^2/day

The study

How the trial runs.

Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle cell lymphoma (MCL) (stratum II) as well as paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes transduced by the third-generation RV-SFG.CD19.CD28.4-1BBzeta retroviral vector.

The main purpose of this study is to evaluate safety and feasibility of escalating CD19.CAR T cell doses (0,1-20×20^7 transduced cells/m^2) after lymphodepletion with fludarabine and cyclophosphamide.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Stratum I/II (Adults):
  • Confirmed CD19+ ALL, CLL, DLBCL, FL or MCL in patients ≥ 18 years
  • ALL (Ph+ and Ph-): Confirmed CD19+ ALL by cytology and flow cytometry (FACS) AND
  • Relapsed or refractory disease (including "molecular relapse" with minimal residual disease (MRD) levels > 10^-3 at two occasions > 2 weeks apart) with confirmed CD19 expression on malignant cells in relapse
  • Any relapse after allogeneic stem cell transplantation (alloSCT) (≥ 6 months from alloSCT at time of CAR T cell infusion) OR
  • Any relapse failing to achieve an MRD level of < 10^-3 after ≥ 2 lines of treatment OR

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.